Emergent BioSolutions Inc. (EBS) caught a nice tailwind Friday after the FDA signed off on new multipack configurations of its over-the-counter Narcan Nasal Spray. If you're a public health organization or harm reduction program distributing naloxone by the truckload, this news matters.

The company announced that the Food and Drug Administration approved its supplemental New Drug Application for 6-count and 24-count multipack options of Narcan Nasal Spray. The 4 mg naloxone formulation was already the first FDA-approved over-the-counter naloxone product for emergency treatment of opioid overdose. Now it just comes in bulk.

The whole point here is distribution flexibility. Organizations that hand out naloxone in high volumes can now order larger pack sizes, which presumably makes logistics easier and potentially more cost-effective. The new multipacks will be available through NARCANDirect, Emergent's proprietary ordering platform, and they complement the recently approved Narcan Nasal Spray Carrying Case.

Here's some context on scale: since Narcan launched in 2016, over 85 million doses have been distributed across the U.S. and Canada. That's a staggering number that underscores both the severity of the opioid crisis and Narcan's central role in emergency response.

What The Charts Are Saying

Emergent BioSolutions is currently trading 2.9% below its 20-day simple moving average and 7.1% below its 50-day SMA, which signals some short-term weakness. But zoom out to the 12-month view and the picture brightens: the stock has gained approximately 14.21% over the past year and sits closer to its 52-week high than its low.

The technical indicators tell a mixed story. RSI is sitting at 41.16, which is neutral territory—neither overbought nor oversold. Meanwhile, MACD is below its signal line, suggesting bearish pressure. So you've got neutral momentum indicators paired with bearish MACD, which doesn't exactly scream "buy now" from a technical perspective.

• Key Resistance: $11.50
• Key Support: $10.50

Healthcare Sector Context

Emergent is outperforming the Healthcare sector, which currently ranks 2 out of 11 sectors with no change from the previous trading day. The sector has had a rough month, declining 1.18% over the past 30 days, though it's up 2.83% over the last 90 days. Emergent's positive product news is helping it stand out against peers in what's been a challenging environment.

Mark your calendars: Emergent BioSolutions is scheduled to report earnings on February 26, 2026. Analysts are expecting EPS of 32 cents, up from 5 cents year-over-year. Revenue estimates come in at $216.50 million, compared to $194.70 million in the prior year. The stock trades at a P/E ratio of 8.2x, which suggests a potential value opportunity.

Analyst Consensus: The stock carries a Buy rating with an average price target of $45. That's a substantial premium to current levels, assuming analysts are in the ballpark.

Quality Metrics And Momentum

Looking at fundamental scoring:

• Value: Strong (Score: 84.14) — The stock appears undervalued relative to peers.
• Quality: Strong (Score: 91.62) — The company maintains a healthy balance sheet.
• Momentum: Bullish (Score: 72.97) — The stock is outperforming the broader market.

The Bottom Line: Emergent scores well on value and quality metrics, which suggests the stock could be an interesting opportunity for investors willing to look past short-term technical weakness. The positive momentum score and recent FDA approval should help sustain interest, particularly as the opioid crisis continues to demand solutions.

ETF Exposure

If you prefer exposure through funds, here's where Emergent shows up:

• Schwab Fundamental US Small Company Index ETF (FNDA): 0.33% Weight
• Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ): 0.42% Weight

Price Action: Emergent BioSolutions shares were up 1.94% at $11.06 during Friday's premarket trading.